Coya Therapeutics, Inc. (COYA)
(Delayed Data from NSDQ)
$5.50 USD
-0.24 (-4.18%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $5.61 +0.11 (2.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
COYA 5.50 -0.24(-4.18%)
Will COYA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for COYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COYA
Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy?
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates
COYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?
Other News for COYA
COYA forms 180 Bearish Setup on September 20
Is COYA ready to move higher? Stochastic Buy Signal shows up after rocketing 6.1%
Lower Bollinger Band Walk appears for COYA after 4.59% move
Coya Therapeutics, Inc. (COYA) Gets a Buy from Lake Street
COYA: Analyst Jason Kolbert Maintains 'Buy' Rating with $18 Target | COYA Stock News